Blueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up

MT Newswires Live

Jan 14, 2025

Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.

The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.

"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment," Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.

The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.

Blueprint Medicines shares were up nearly 10% in recent trading.

Price: 95.82, Change: +8.39, Percent Change: +9.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503533899"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503533899\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503533899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 01:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503533899","market":"us","top_or_hot":-1,"title":"Blueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up","media":"MT Newswires Live","content":"<html><body><p> Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.</p><p>The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.</p><p>\"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment,\" Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.</p><p>The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.</p><p>Blueprint Medicines shares were up nearly 10% in recent trading.</p><p>Price: 95.82, Change: +8.39, Percent Change: +9.60</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlueprint Medicines Expects Systemic Mastocytosis Franchise to Generate $4 Billion by 2030 -- Shares Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-14 01:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.</p><p>The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.</p><p>\"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment,\" Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.</p><p>The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.</p><p>Blueprint Medicines shares were up nearly 10% in recent trading.</p><p>Price: 95.82, Change: +8.39, Percent Change: +9.60</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503533899","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503533899","pubTimestamp":1736788358,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Blueprint Medicines  said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.\"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment,\" Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.Blueprint Medicines shares were up nearly 10% in recent trading.Price: 95.82, Change: +8.39, Percent Change: +9.60","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4505":"高瓴资本持仓","BK4139":"生物科技","BPMC":"Blueprint Medicines Corporation"},"translate_title":"Blueprint Medicines预计到2030年系统性肥大细胞增多症特许经营权将产生40亿美元的收入——股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":1},"content_text":"Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.\"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment,\" Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.Blueprint Medicines shares were up nearly 10% in recent trading.Price: 95.82, Change: +8.39, Percent Change: +9.60","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}